Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03664752 · ClinicalTrials.gov registry record · Phase 3
Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris
A Phase 3 study, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 3
- Development phase
- 585
- Enrollment target
NCT03664752: Completed Phase 3 study, sponsored by Bausch Health Americas.
NCT03664752 is a Phase 3 study that has completed, run by Bausch Health Americas. The registered enrollment target is 585 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (24% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03664752, a Phase 3 study, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 585 participants
- Enrollment target
Study Summary
study designed to assess the safety, tolerability, and efficacy of IDP-120 Gel and IDP-120 Vehicle Gel
Primary Outcome
For noninflammatory facial lesions, open comedones (blackheads) and closed comedones (whiteheads) were recorded as a single count. For inflammatory facial lesions, papules (solid, elevated lesion less than 5 mm) and pustules (elevated lesion containing pus less than 5 mm) were recorded as a single count, while nodular lesions (palpable subcutaneous lesion greater than 5 mm) were counted and recorded separately.
Interventions
- DRUG IDP-120 Gel
- DRUG IDP-120 Vehicle Gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 585 participants |
| Start Date | 2018-12-10 |
| Est. Completion | 2020-05-07 |
| Phase | Phase 3 |
What the finished NCT03664752 record still lists
NCT03664752 is an interventional study that assigns participants to a tested intervention. The registered 585 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (24% lower).
The record links to 0 conditions, and to 2 interventions - of which IDP-120 Gel is the first listed.
NCT03664752 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03664752 about?
NCT03664752 is a clinical study titled "Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris". study designed to assess the safety, tolerability, and efficacy of IDP-120 Gel and IDP-120 Vehicle Gel
What is the current status of trial NCT03664752?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 585 participants. The study started on 2018-12-10. Estimated completion is 2020-05-07.
What interventions are being tested in trial NCT03664752?
The interventions under investigation include: IDP-120 Gel (DRUG), IDP-120 Vehicle Gel (DRUG).
Who is sponsoring clinical trial NCT03664752?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03664752's enrollment target sits among peer trials
585 651st of 2000 higher than 1,349 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02803957 · 585 participants · NA
Randomized Trial of the Neochord DS1000 System Versus Open Surgical Repair
- NCT06680869 · 585 participants · Phase 3
Early Amiodarone in Shockable Cardiac Arrest
- NCT04134260 · 586 participants · Phase 3
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
- NCT06100770 · 586 participants
Aveir AR Coverage With Evidence Development (CED) Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI